Biosimilars of Avastin and Herceptin are approved in the United States
Updated: Aug 29, 2019
Mvasi (bevacizumab) biosimilar of Avastin and Kanjinti (trastuzumab) biosimilar of Herceptin were now available in the United States.
Mvasi is approved in the US for
Metastatic colorectal cancer (mCRC) in combination
Non-squamous non-small cell lung cancer in combination
Metastatic renal cell carcinoma
Metastatic cervical cancer
Kanjinti is approved in the US for
HER2-over expressing adjuvant and metastatic breast cancer
HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Mvasi is available at $677.40 per 100 mg and $2,709.60 per 400 mg single-dose vial (WAC price). The price is 15% less than the branded product.
Kanjinti is available at $3,697.26 per 420 mg multi-dose vial. The price is 12% less than the branded product.
Amgen has 10 biosimilars, 3 were approved in the United States.
The out-of-pocket cost was significantly lesser than WAC prices.